On behalf of the SFGM-TC: Real-life use of third-party virus-specific T-cell transfer in immunocompromised transplanted patients.

Autor: Leroyer EH; Department of Hematology Nancy University Hospital Vandoeuvre-les-Nancy France., Petitpain N; Regional Centre of Pharmacovigilance Nancy University Hospital Vandoeuvre-les-Nancy France., Morisset S; Statistical Unit Pérouges France., Neven B; Assistance Publique des Hôpitaux de Paris, Department of Pediatric Immuno-hematology Necker Children Hospital Paris France., Castelle M; Assistance Publique des Hôpitaux de Paris, Department of Pediatric Immuno-hematology Necker Children Hospital Paris France., Winter S; Assistance Publique des Hôpitaux de Paris, Department of Pediatric Immuno-hematology Necker Children Hospital Paris France., Souchet L; Assistance Publique des Hôpitaux de Paris, Department of Hematology La Pitié-Salpêtrière Hospital Paris France., Morel V; Assistance Publique des Hôpitaux de Paris, Department of Hematology La Pitié-Salpêtrière Hospital Paris France., Le Cann M; Assistance Publique des Hôpitaux de Paris, Department of Hematology La Pitié-Salpêtrière Hospital Paris France., Fahd M; Department of Pediatric Hematology and Immunology, Robert Debré Academic Hospital GHU APHP Nord Université Paris Cité Paris France., Yacouben K; Department of Pediatric Hematology and Immunology, Robert Debré Academic Hospital GHU APHP Nord Université Paris Cité Paris France., Mechinaud F; Department of Pediatric Hematology and Immunology, Robert Debré Academic Hospital GHU APHP Nord Université Paris Cité Paris France., Ouachée-Chardin M; Institute of Pediatric Hematology and Oncology (IHOPe) Hospices Civils de Lyon and Claude Bernard University Lyon France., Renard C; Institute of Pediatric Hematology and Oncology (IHOPe) Hospices Civils de Lyon and Claude Bernard University Lyon France., Wallet HL; Institute of Pediatric Hematology and Oncology (IHOPe) Hospices Civils de Lyon and Claude Bernard University Lyon France., Angoso M; Department of Pediatric Hematology Oncology University Hospital of Bordeaux Bordeaux France., Jubert C; Department of Pediatric Hematology Oncology University Hospital of Bordeaux Bordeaux France., Chevallier P; Department of Hematology Nantes University Hospital Nantes France., Léger A; Department of Pediatric Hematology, Hôpital Mère-Enfant Nantes University Hospital Nantes France., Rialland F; Department of Pediatric Hematology, Hôpital Mère-Enfant Nantes University Hospital Nantes France., Dhedin N; Assistance Publique des Hôpitaux de Paris, Department of Hematology Saint-Louis Hospital Paris France., Robin C; Assistance Publique des Hôpitaux de Paris, Department of Hematology Henri Mondor Hospital and Université Créteil France., Maury S; Assistance Publique des Hôpitaux de Paris, Department of Hematology Henri Mondor Hospital and Université Créteil France., Beckerich F; Assistance Publique des Hôpitaux de Paris, Department of Hematology Henri Mondor Hospital and Université Créteil France., Beauvais D; Department of Hematology, Allogeneic Stem Cell Transplantation Unit Lille University Hospital Lille France., Cluzeau T; Department of Hematology, Université Cote d'Azur Nice University Hospital Nice France., Loschi M; Department of Hematology, Université Cote d'Azur Nice University Hospital Nice France., Fernster A; Hôpital Universitaire des Enfants de la Reine Fabiola, Department of Pediatric Hematology Brussels University Hospital Brussels Belgium., Bittencourt MC; Cytometry Platform Nancy University Hospital Vandoeuvre-les-Nancy France.; EFS La Plaine St Denis St Denis France., Cravat M; Cytometry Platform Nancy University Hospital Vandoeuvre-les-Nancy France., Bilger K; INCANS Department of Hematology Strasbourg France., Clément L; Department of Hematology Bordeaux University Hospital Bordeaux France., Decot V; Cell Therapy Unit Nancy University Hospital Vandoeuvre-les-Nancy France., Gauthier M; Cell Therapy Unit Nancy University Hospital Vandoeuvre-les-Nancy France., Legendre A; EFS La Plaine St-Denis France., Larghero J; Assistance Publique des Hôpitaux de Paris, Cell Therapy Unit, INSERM CICBT 501 Saint-Louis Hospital Paris France., Ouedrani A; Assistance Publique des Hôpitaux de Paris, Department of Immunology and Histocompatibily Saint-Louis Hospital Paris France., Martin-Blondel G; Department of Infectious and Tropical Diseases, and Toulouse Institute for Infectious and Inflammatory Diseases, INSERM UMR1291-CNRS UMR5051-Université Toulouse III Toulouse University Hospital Toulouse France., Pochon C; Department of Pediatric Hematology Nancy University Hospital Vandoeuvre-les-Nancy France.; CNRS Unit UMR 7365 IMoPA Lorraine University Vandoeuvre-les-Nancy France., Reppel L; Cell Therapy Unit Nancy University Hospital Vandoeuvre-les-Nancy France.; CNRS Unit UMR 7365 IMoPA Lorraine University Vandoeuvre-les-Nancy France., Rouard H; EFS La Plaine St Denis St Denis France., Nguyen-Quoc S; Assistance Publique des Hôpitaux de Paris, Department of Hematology La Pitié-Salpêtrière Hospital Paris France., Dalle JH; Department of Pediatric Hematology and Immunology, Robert Debré Academic Hospital GHU APHP Nord Université Paris Cité Paris France., D'Aveni M; Department of Hematology Nancy University Hospital Vandoeuvre-les-Nancy France.; CNRS Unit UMR 7365 IMoPA Lorraine University Vandoeuvre-les-Nancy France., Bensoussan D; Cell Therapy Unit Nancy University Hospital Vandoeuvre-les-Nancy France.; CNRS Unit UMR 7365 IMoPA Lorraine University Vandoeuvre-les-Nancy France.

Publikováno v: HemaSphere [Hemasphere] 2024 Jan 27; Vol. 8 (1), pp. e40. Date of Electronic Publication: 2024 Jan 27 (Print Publication: 2024).

Efficacy of Wharton Jelly Mesenchymal Stromal Cells infusions in moderate to severe SARS-Cov-2 related acute respiratory distress syndrome: a phase 2a double-blind randomized controlled trial.

Autor: Pochon C; CHRU-Nancy, Pediatric Onco-Hematology Department, Nancy, France.; Team 6 IMoPA, UMR 7365 CNRS-UL, Université de Lorraine, Nancy, France., Laroye C; Team 6 IMoPA, UMR 7365 CNRS-UL, Université de Lorraine, Nancy, France.; CHRU-Nancy, Unité de Thérapie Cellulaire et banque de tissus, Nancy, France., Kimmoun A; CHRU-Nancy, Service de Médecine Intensive et Réanimation, Hôpitaux de Brabois, Nancy, France.; Université de Lorraine, Nancy, France., Reppel L; Team 6 IMoPA, UMR 7365 CNRS-UL, Université de Lorraine, Nancy, France.; CHRU-Nancy, Unité de Thérapie Cellulaire et banque de tissus, Nancy, France., Dhuyser A; CHRU-Nancy, HLA and Histocompatibility Laboratory, Nancy, France., Rousseau H; CHRU-Nancy, Département Méthodologie, Promotion, Investigation, Hôpitaux de Brabois, Nancy, France., Gauthier M; Team 6 IMoPA, UMR 7365 CNRS-UL, Université de Lorraine, Nancy, France.; CHRU-Nancy, Unité de Thérapie Cellulaire et banque de tissus, Nancy, France., Petitpain N; CHRU-Nancy, Département de Pharmacovigilance, Hôpitaux de Brabois, Nancy, France., Chabot JF; CHRU-Nancy, Pôle des Spécialités Médicales/Département de Pneumologie, Hôpitaux de Brabois, Nancy, France., Valentin S; CHRU-Nancy, Pôle des Spécialités Médicales/Département de Pneumologie, Hôpitaux de Brabois, Nancy, France., de Carvalho Bittencourt M; CHRU-Nancy, Laboratoire d'immunologie, Hôpitaux de Brabois, Nancy, France., Peres M; CHRU-Nancy, HLA and Histocompatibility Laboratory, Nancy, France., Aarnink A; Team 6 IMoPA, UMR 7365 CNRS-UL, Université de Lorraine, Nancy, France.; CHRU-Nancy, HLA and Histocompatibility Laboratory, Nancy, France., Decot V; Team 6 IMoPA, UMR 7365 CNRS-UL, Université de Lorraine, Nancy, France.; CHRU-Nancy, Unité de Thérapie Cellulaire et banque de tissus, Nancy, France., Bensoussan D; Team 6 IMoPA, UMR 7365 CNRS-UL, Université de Lorraine, Nancy, France.; CHRU-Nancy, Unité de Thérapie Cellulaire et banque de tissus, Nancy, France., Gibot S; CHRU-Nancy, Service de Médecine Intensive et Réanimation, Hôpital Central, Nancy, France.

Publikováno v: Frontiers in medicine [Front Med (Lausanne)] 2023 Aug 29; Vol. 10, pp. 1224865. Date of Electronic Publication: 2023 Aug 29 (Print Publication: 2023).

Systematic Review on CAR-T Cell Clinical Trials Up to 2022: Academic Center Input.

Autor: Wang V; CNRS, Lorraine University, IMoPA, F-54000, Nancy, France., Gauthier M; CNRS, Lorraine University, IMoPA, F-54000, Nancy, France.; Cell Therapy and Tissue Bank Unit, CHRU Nancy, F-54000, Nancy, France., Decot V; CNRS, Lorraine University, IMoPA, F-54000, Nancy, France.; Cell Therapy and Tissue Bank Unit, CHRU Nancy, F-54000, Nancy, France., Reppel L; CNRS, Lorraine University, IMoPA, F-54000, Nancy, France.; Cell Therapy and Tissue Bank Unit, CHRU Nancy, F-54000, Nancy, France., Bensoussan D; CNRS, Lorraine University, IMoPA, F-54000, Nancy, France.; Cell Therapy and Tissue Bank Unit, CHRU Nancy, F-54000, Nancy, France.

Publikováno v: Cancers [Cancers (Basel)] 2023 Feb 04; Vol. 15 (4). Date of Electronic Publication: 2023 Feb 04.

Adverse Mechanical Ventilation and Pneumococcal Pneumonia Induce Immune and Mitochondrial Dysfunctions Mitigated by Mesenchymal Stem Cells in Rabbits.

Autor: Blot M; From INSERM (Institut National de la Santé et de la Recherche Médicale), LabEx LipSTIC, Université de Bourgogne Franche-Comté, LNC Mixed Research Unit 1231, Dijon, France; the Infectious Diseases Department., Jacquier M; From INSERM (Institut National de la Santé et de la Recherche Médicale), LabEx LipSTIC, Université de Bourgogne Franche-Comté, LNC Mixed Research Unit 1231, Dijon, France; the Intensive Care Unit, University Hospital, Dijon, France., Pauchard LA; From INSERM (Institut National de la Santé et de la Recherche Médicale), LabEx LipSTIC, Université de Bourgogne Franche-Comté, LNC Mixed Research Unit 1231, Dijon, France., Rebaud C; From INSERM (Institut National de la Santé et de la Recherche Médicale), LabEx LipSTIC, Université de Bourgogne Franche-Comté, LNC Mixed Research Unit 1231, Dijon, France., Marlin C; From INSERM (Institut National de la Santé et de la Recherche Médicale), LabEx LipSTIC, Université de Bourgogne Franche-Comté, LNC Mixed Research Unit 1231, Dijon, France., Hamelle C; From INSERM (Institut National de la Santé et de la Recherche Médicale), LabEx LipSTIC, Université de Bourgogne Franche-Comté, LNC Mixed Research Unit 1231, Dijon, France., Bataille A; the CellImaP Core Facility, INSERM LNC Mixed Research Unit 1231, Dijon, France., Croisier D; the Vivexia, Gemeaux, France., Thomas C; From INSERM (Institut National de la Santé et de la Recherche Médicale), LabEx LipSTIC, Université de Bourgogne Franche-Comté, LNC Mixed Research Unit 1231, Dijon, France., Jalil A; From INSERM (Institut National de la Santé et de la Recherche Médicale), LabEx LipSTIC, Université de Bourgogne Franche-Comté, LNC Mixed Research Unit 1231, Dijon, France., Mirfendereski H; the Pharmacology Department, University of Poitiers, INSERM U1070, Poitiers, France., Piroth L; the Infectious Diseases Department., Chavanet P; the Infectious Diseases Department., Bensoussan D; the Cell Therapy and Tissue Banking Unit, Lorraine University Hospital, Vandoeuvre-lès-Nancy, France., Laroye C; the Cell Therapy and Tissue Banking Unit, Lorraine University Hospital, Vandoeuvre-lès-Nancy, France., Reppel L; the Cell Therapy and Tissue Banking Unit, Lorraine University Hospital, Vandoeuvre-lès-Nancy, France; the IMoPA, National Center for Scientific Research-Lorraine University, Mixed Research Unit 7365, Vandoeuvre-lès-Nancy, France., Charles PE; From INSERM (Institut National de la Santé et de la Recherche Médicale), LabEx LipSTIC, Université de Bourgogne Franche-Comté, LNC Mixed Research Unit 1231, Dijon, France; the Intensive Care Unit, University Hospital, Dijon, France.

Publikováno v: Anesthesiology [Anesthesiology] 2022 Feb 01; Vol. 136 (2), pp. 293-313.

Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer.

Autor: Reppel L; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA., Tsahouridis O; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA., Akulian J; Division of Pulmonary and Critical Care, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA., Davis IJ; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.; Department of Pediatrics, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA., Lee H; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA., Fucà G; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA., Weiss J; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.; Division of Oncology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA., Dotti G; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.; Department of Microbiology and Immunology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA., Pecot CV; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.; Division of Oncology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA., Savoldo B; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA bsavoldo@med.unc.edu.; Department of Pediatrics, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Jan; Vol. 10 (1).